Leerink Partnrs Brokers Lift Earnings Estimates for KPTI

Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Free Report) – Research analysts at Leerink Partnrs upped their Q3 2025 EPS estimates for shares of Karyopharm Therapeutics in a research note issued to investors on Monday, August 11th. Leerink Partnrs analyst J. Chang now anticipates that the company will earn ($3.26) per share for the quarter, up from […]

Leave a Reply

Your email address will not be published.

Previous post CIBC Issues Positive Forecast for Nexus Industrial REIT (TSE:NXR.UN) Stock Price
Next post 10th annual Philando Castile event raises scholarship money in his name